Business Wire

RMS Launches New Products and Models on RMS Risk Intelligence, the Unified Cloud Platform for Global Risk

Share

As the world is changing in profound ways, so is risk. Climate change, pandemic events, and cyberattacks are threats we all now have to consider in new and innovative ways. With better understanding of risks, better decisions can be made, enabling better risk management end-to-end. Today, at the opening of its annual Exceedance conference, RMS, the world’s leading catastrophe risk solutions company, announced significant new model and product releases and updates for RMS Risk Intelligence™ (RI).

RMS Risk Intelligence (RI), first launched in May 2019, is an open, modular, unified, and reliable cloud platform that enables advanced modeling, deeper risk insights and analytics. Leveraging a cloud-native architecture, RI delivers higher performance and scale. With the RMS Risk Intelligence platform, there is no hardware or software to maintain, focused on reducing cost of ownership. The platform enables (re)insurers, the capital market, governments, and other organizations to efficiently operate and manage all their RMS risk models in the cloud, with an intuitive user experience, integrated with advanced risk analytics. RI is compliant with all industry recognized best-in-class security requirements such as GDPR, ISO27001, C5 and SOC2.

This week, during the virtual Exceedance 2020 conference, RMS will demonstrate significant advancements on RMS Risk Intelligence.

Risk Modeler 2.0

Risk Modeler 2.0™ is a break-through product release at RMS, running on RMS Risk Intelligence. Risk Modeler 2.0 provides advanced portfolio and account risk analyses leveraging RMS models and is designed to meet the complex needs of risk analysts and cat modelers. The latest version of the Risk Modeler product enables real-time risk analytics and unified, high performance execution of RiskLink® models and HD Models. It can also be easily integrated with on-premises modeling and other on-premises applications as well as other cloud applications through open APIs, giving customers maximum flexibility and choice. Risk Modeler 2.0 offers an all-in-one RiskLink and RiskBrowser experience, with familiar features along with an enhanced, intuitive user interface that streamlines workflows to reduce the time and steps it takes to complete complex analyses. Risk Modeler 2.0 is a unified modeling and analytics solution for an entire organization to run portfolio and account modeling workflows, promoting real-time risk insights.

Risk Modeler 2.0 provides:

  • Global risk model coverage in North America, Europe, and Asia, with RiskLink versions 18.0 and 18.1 of core models, HD Models and specialty models
  • Future-proof architecture for model engines that unify execution of RiskLink and HD Models under one roof
  • Faster model execution. For some of the most popular RiskLink Models such as North Atlantic Hurricane, North America Earthquake, Europe Windstorm and North America Winterstorm, plus others that run four to six times faster on a one million location portfolio
  • Simplified integration with existing systems with support for a rich set of data formats, from Exposure Data Module (EDM), Results Data Module (RDM), event loss tables (ELT) to period loss tables (PLT), and year loss tables (YLT)
  • Zero-downtime upgrades and faster access to models with side-by-side model versions in one application
  • Intuitive and familiar workflows including for RiskLink and RiskBrowser users
  • Simplified usability, with batch processing of multiple steps such as the data upload process, now reduced to one-step
  • API integration with third-party tools and in-house applications to enable a fully automated modeling end-to-end process, e.g., importing exposures, running geocoding and hazard lookup services

Risk Modeler 2.0 is available to customers in preview today and will be generally available with RiskLink models, with initial HD models in preview, by June 2020.

Risk Modeler with New HD Models

RMS High Definition Models are the next generation of risk modeling, delivering greater analysis and granularity than ever before. RMS HD Models have now all undergone a significant upgrade as they transitioned to the Risk Modeler application, which gives them greater flexibility and computational strength. The following models are in addition to the US Flood and US Wildfire HD Models that have been available through Risk Modeler’s earlier version:

  • Updated Europe Inland Flood Model suite that covers 18 river basins and over 8,000 catchments across 15 countries in Europe
  • Updated Japan Earthquake and Tsunami and New Zealand Earthquake models that both include sub-peril coverage for tsunami, fire-following, liquefaction and landslides
  • Updated Japan Typhoon and Flood Model that incorporates the most recent events such as Typhoons Jebi and Hagibis
  • Europe Severe Convective Storm Models, a brand new model suite that covers 17 countries with large pan-European event sets and is fully integrated with our Europe Windstorm Model.

All these HD Models are available today, and will be generally available between June and September 2020 in the Risk Modeler 2.0 application. Customers can evaluate and validate these models even earlier with the preview program for Risk Modeler, or through Analytical Services. Customers can access the Europe Inland Flood and US Wildfire Models starting in June on Risk Modeler 2.0, followed by Europe Severe Convective Storm, Japan Typhoon, Japan Earthquake and New Zealand Earthquake Models coming onto Risk Modeler 2.0 shortly after. All HD models will be generally available on the new Risk Modeler 2.0 by September 2020.

Analytical Application Suite

RMS Risk Intelligence also offers a new suite of advanced applications that are tailored for specific portfolio management and underwriting tasks. These include:

  • ExposureIQ™ – This new application ensures portfolio managers gain deeper insights into their books with millions of locations, enabling easy discovery of hotspots, diversification and re-balancing their portfolio. The ExposureIQ application provides real-time exposure information combined with wind forecasting events and footprints from RMS Event Response to help gain a quicker assessment of potential losses before, during and after an event. Customers may gain advanced preview access to the Exposure IQ application and it will be generally available June 2020.
  • Next versions of SiteIQ™ and Location Intelligence APIs-Rigorous catastrophe peril risk assessment can now be done in seconds, early in the underwriting process. The RMS SiteIQ and Location Intelligence APIs have been enhanced in these latest versions to provide fast and easy access to over 100 trillion data points and can now deliver over 200 data points per location in some regions, with current (and expanding) coverage of over 70+ countries.
  • TreatyIQ- Harnessing a massively scalable roll-up engine, a trusted financial model, and flexible contract languages, the TreatyIQ application enables property treaty underwriters to achieve greater return on capacity with pricing and portfolio roll-up analytics. The Treaty IQ application will be available in preview summer 2020 and will be generally available September 2020.

Cihan Biyikoglu, Executive Vice President, Product, at RMS, said: “The significant advancements that the RMS team has made across all our products, HD Models, and especially Risk Modeler have been possible through collaboration with more than 400 RMS customers this past year. The Risk Intelligence unified cloud platform, through its innovative use of the risk data lake, the Risk Data Open Standard (RDOS), unified modeling and IQ applications - securely brings greater scale, capabilities and risk insights to the market. I am also excited about what the future holds in terms of new products and technologies. Further developments of the machine learning and artificial intelligence tools used by RMS will continue to open greater opportunities.”

Karen White, Chief Executive Officer at RMS said, “Risk Intelligence is the world’s first comprehensive global risk platform. The complexity and connectedness of risks continually confront us - we are all experiencing the crisis of COVID-19, along with the persistent crises of climate change, extreme weather and growing cyber threats. Facing all this, our industry needs a modern risk platform that takes advantage of all manner of data, modeling and analytics, in a way that is fast, integrated, and leverages technology in new ways for better insights and outcomes. RMS promised innovation, and with Risk Modeler 2.0 and the IQ applications, we have delivered – with an integrated platform for modeling risk in the cloud at the scale and speed required to take on the future of risk.”

ENDS

Notes to editors:

About RMS:

Risk Management Solutions, Inc. (RMS) helps insurers, financial markets, corporations, and public agencies evaluate and manage global risk from natural and man-made catastrophes, including hurricanes, earthquakes, floods, climate change, cyber, and pandemics.

RMS leads the catastrophe risk industry that we helped to pioneer by marrying data and advanced model science with leading-edge technology. Leaders across multiple industries can address the risks of tomorrow through RMS Risk Intelligence™, our open, real-time exposure and risk management platform, enabling them to tap into RMS HD models, rich data layers, intuitive applications and APIs that simply integrate into existing enterprise systems.

RMS is a trusted solutions partner enabling effective risk management for better business decision making across underwriting, risk selection, mitigation, and portfolio management.

Visit RMS.com to learn more and follow us on LinkedIn and Twitter.

Contact information

Matthew Longbottom (U.K.)
+44 (0) 7584 333485
prteam@rms.com

Devonne Cusi (U.S.)
+1 551 226 1604
prteam@rms.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 06:00:00 CESTPress release

Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 03:00:00 CESTPress release

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom